XELLIA PHARMS APS
GenericsXELLIA PHARMS APS is a generic drug manufacturer focused on Infectious Disease, Dermatology.
XELLIA PHARMS APS's Key Drugs
XELLIA PHARMS APS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
XELLIA PHARMS APS's Recent FDA Approvals
XELLIA PHARMS APS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
XELLIA PHARMS APS's Therapeutic Areas
XELLIA PHARMS APS's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
XELLIA PHARMS APS's Top Competitors
XELLIA PHARMS APS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
XELLIA PHARMS APS Pipeline Snapshot
Active clinical trials for XELLIA PHARMS APS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2014-01-15
- Latest
- 2025-07-03
- Applications
- 10